Lamisil Dermgel (Terbinafine)

Terbinafine belongs to the allylamine class of antifungals. It blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. Inhibition leads to toxic squalene buildup and loss of membrane integrity, ultimately killing the fungus.

The dosing regimen for Lamisil Dermgel is determined by the prescribing healthcare professional. Typically, a thin layer of the gel is applied once daily to the clean, dry affected skin for a period specified by the prescriber, which may range from one to several weeks depending on the infection.

Safety data for topical terbinafine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order Lamisil Dermgel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Compared with azole antifungals such as clotrimazole or miconazole, terbinafine often achieves faster clinical cure rates for dermatophyte infections because it acts on a different enzymatic pathway. It is also generally well‑tolerated, but choice of therapy should consider infection type, patient history and local resistance patterns.

Lamisil Dermgel should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from direct sunlight and moisture, and keep it out of reach of children.

Apply a thin layer of the gel to the clean, dry affected skin area once daily, as directed by a healthcare professional. Gently rub it in until it disappears, and wash hands after application unless the hands are the treatment site.

Although rare, serious adverse reactions can include severe allergic responses such as swelling, hives, or difficulty breathing (anaphylaxis), and systemic effects like liver enzyme elevation. Patients should seek immediate medical attention if they experience signs of a serious reaction.

Lamisil Dermgel should be avoided in individuals with known hypersensitivity to terbinafine or any component of the formulation. It is also not recommended for infants under two years of age or for use on severely damaged, inflamed or eczematous skin without medical supervision.